Your browser doesn't support javascript.
loading
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, Richard; Obrtlíková, Petra; Smolej, Lukás; Kozák, Tomás; Steurer, Michael; Andel, Johannes; Burgstaller, Sonja; Mikusková, Eva; Gercheva, Liana; Nösslinger, Thomas; Papajík, Tomás; Ladická, Miriam; Girschikofsky, Michael; Hrubisko, Mikulás; Jäger, Ulrich; Fridrik, Michael; Pecherstorfer, Martin; Králiková, Eva; Burcoveanu, Cristina; Spasov, Emil; Petzer, Andreas; Mihaylov, Georgi; Raynov, Julian; Oexle, Horst; Zabernigg, August; Flochová, Emília; Palásthy, Stanislav; Stehlíková, Olga; Doubek, Michael; Altenhofer, Petra; Pleyer, Lisa; Melchardt, Thomas; Klingler, Anton; Mayer, Jirí; Egle, Alexander.
Affiliation
  • Greil R; Third Medical Department at the Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria; Cancer Cluster Salzburg (CCS), Salzburg, Austria. Electronic address: r.greil@salk.at.
  • Obrtlíková P; First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
  • Smolej L; Fourth Department of Internal Medicine-Hematology, University Hospital and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic.
  • Kozák T; Department of Internal Medicine-Hematology, Univ Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Steurer M; Department of Internal Medicine V, Medical University Innsbruck, Austria.
  • Andel J; Abteilung für Innere Medizin III, Landeskrankenhaus Steyr, Austria.
  • Burgstaller S; Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen GmbH, Austria.
  • Mikusková E; Department of Hematooncology 2, National Cancer Institute, Bratislava, Slovakia.
  • Gercheva L; Clinic of Hematology, University Hospital St Marina, Varna, Bulgaria.
  • Nösslinger T; Third Medical Department for Hematology and Oncology, Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna, Austria.
  • Papajík T; Department of Hemato-oncology, University Hospital, Olomouc, Czech Republic.
  • Ladická M; Department of Clinical Oncology 1, National Cancer Institute, Bratislava, Slovakia.
  • Girschikofsky M; I Interne Abteilung, Elisabethinen Krankenhaus, Linz, Austria.
  • Hrubisko M; Clinic of Hematology and Transfusiology, Slovak Medical University, University Hospital Bratislava, Slovakia.
  • Jäger U; Department of Medicine I, Division of Hematology and Hemostaeology, Medical University Vienna, Austria.
  • Fridrik M; Department of Internal Medicine 3, Kepler Universitätsklinikum GmbH, Med Campus III, Linz, Austria.
  • Pecherstorfer M; University Hospital Krems, Karl Landsteiner Private University of Health Sciences, Department of Internal Medicine 2, Krems, Austria.
  • Králiková E; Department of Hematology, FNsP F D Roosevelta, Banská Bystrica, Slovakia.
  • Burcoveanu C; Clinic of Haematology, Regional Institute of Oncology Iasi, Iasi, Romania.
  • Spasov E; Clinic of Hematology, UMHAT St George and Medical University, Plovdiv, Bulgaria.
  • Petzer A; Innere Medizin I, Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria.
  • Mihaylov G; Hematological Clinic NSHATHD, Sofia, Bulgaria.
  • Raynov J; Clinic of Medical Hematology, Military Medical Academy, Sofia, Bulgaria.
  • Oexle H; Innere Medizin, Landeskrankenhaus Hall, Austria.
  • Zabernigg A; Innere Medizin II, Bezirkskrankenhaus Kufstein, Austria.
  • Flochová E; Department of Hematology and Transfusion, University Hospital Martin, Martin, Slovakia.
  • Palásthy S; Department of Clinical Hematology, FNsP, J A Reimana, Presov, Slovakia.
  • Stehlíková O; University Hospital, Faculty of Medicine and CEITEC, Brno, Czech Republic.
  • Doubek M; University Hospital, Faculty of Medicine and CEITEC, Brno, Czech Republic.
  • Altenhofer P; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Pleyer L; Third Medical Department at the Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Melchardt T; Third Medical Department at the Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
  • Klingler A; Assign Data Management and Biostatistics GmbH, Innsbruck, Austria.
  • Mayer J; University Hospital, Faculty of Medicine and CEITEC, Brno, Czech Republic.
  • Egle A; Third Medical Department at the Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute (SCRI), Salzburg, Austria; Cancer Cluster Salzburg (CCS), Salzburg, Austria.
Lancet Haematol ; 3(7): e317-29, 2016 Jul.
Article in En | MEDLINE | ID: mdl-27374465
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Rituximab / Immunotherapy Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2016 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Rituximab / Immunotherapy Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2016 Document type: Article Country of publication: